JPMorgan Chase CEO Warns of Rising Expenses Teases Up to 20 Billion MA Opportunity SpaceX IPO Would Early Investors Be Set for Life A Look at the Potential MegaIPOs from SpaceX and OpenAI Spark Market Top Concerns as Record Floats Approach Roundhill Memory ETF Surpasses 10 Billion in Record Time Amid AI Memory Bottleneck Focus Music Catalogs Attract Institutional Capital as SonyGIC Joint Venture Acquires Recognition Music Group for 4 Billion Singapore Bankruptcy Rise Overspending and Business Failures as Key Drivers DOMH Q1 2024 Earnings Reported EPS of 035 Amid Operational Challenges Kyntra Bio Inc KYNB Q1 2026 Earnings WiderthanExpected Loss Fails to Dampen Investor Sentiment Xylem Q1 2026 Earnings EPS Slightly Above Estimates Amid Operational Strength Webster Financial Q1 2026 Earnings EPS Tops Estimates Despite Market Softness BAH Q1 2026 Earnings Strong EPS Beat Drives Positive Stock Reaction MBINN Q1 2026 Earnings EPS Beats Estimates Depositary Shares Rise iPower Inc IPW Faces Steep Decline as Shares Test Critical Support Zone Reading International Inc RDI Surges 86 Momentum Building Above Key Support Chain Bridge Bancorp CBNA Edges Higher as Stock Holds Above Critical Support TVACU Holds Steady at 1075 as SPAC Units Trade Flat Farmer Brothers FARM Holds Steady Near Support as Trading Volume Remains Light ADT Q1 2026 Earnings Earnings Beat Estimates Despite Flat Revenue Disclosure Lucid Group LCID Q1 2026 Earnings Wider Loss Than Expected as Production Ramp Challenges Persist Intercontinental Exchange ICE Q1 2026 Earnings EPS Beats Estimates by 29 Stock Edges Higher Saratoga Investment Corp 600 Notes due 2027 SAT Q1 2026 Earnings Significant EPS Miss Amid Challenging Market Conditions FRAF Q1 2026 Earnings Earnings Beat Estimates on 828 Surprise Shares Edge Higher PRLD Q1 2026 Earnings NarrowerThanExpected Loss as Clinical Pipeline Advances US Prioritizes American AI Integration in Asia Following TrumpXi Meeting Western Copper and Gold WRN Q1 2026 Earnings WiderThanExpected Loss Amid PreRevenue Development Stage Telomir Pharmaceuticals TELO Holds Steady at 129 as Consolidation Persists